180.15 0.00 (0.00%)
After hours: 6:07PM EDT
|Bid||180.36 x 800|
|Ask||183.99 x 900|
|Day's Range||179.61 - 183.10|
|52 Week Range||145.37 - 195.81|
|Beta (3Y Monthly)||1.22|
|PE Ratio (TTM)||21.71|
|Earnings Date||Jul 23, 2019 - Jul 29, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||208.86|
Vertex's (VRTX) Symdeko gets FDA approval to treat underlying cause of cystic fibrosis in children aged 6-11 years with certain mutations in the CFTR gene.
Vertex Pharmaceuticals Incorporated (VRTX) today announced the U.S. Food and Drug Administration (FDA) approved SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) for use in children with cystic fibrosis ages 6 through 11 years who have two copies of the F508del-CFTR mutation or who have at least one mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is responsive to SYMDEKO. It was previously approved by the FDA for use in patients with cystic fibrosis 12 years and older with two copies of the F508del mutation or one copy of a responsive mutation in the U.S. An additional dosage strength of SYMDEKO tablets is now available (tezacaftor 50 mg/ivacaftor 75 mg and ivacaftor 75 mg) in connection with this approval.
We highlight a few leading players from the biotech sector, having surpassed the same so far in 2019 and are likely to put up a good show during the second half of 2019 as well.
The Zacks Analyst Blog Highlights: Deere, Las Vegas Sands, Vertex, Tesla and Keurig Dr Pepper
Glaxo (GSK) signs a five-year collaboration contract with the University of California to build a new laboratory for developing new medicines with the aid of CRISPR technologies.
CRISPR Therapeutics (CRSP) is set to receive $175 million in upfront payment from Vertex following the expansion of the collaboration agreement for gene editing program to include new disease areas.
Vertex Pharmaceuticals recently doubled down on its gene editing collaboration with CRISPR Therapeutics, but it's miles behind an arguably simpler solution.
Vertex (VRTX) is expanding its gene editing pipeline into new disease areas by expanding collaboration with CRISPR Therapeutics and acquiring Exonics.
Vertex Pharmaceuticals Incorporated (VRTX) today announced that the company is enhancing its gene editing capabilities to develop novel therapies for Duchenne Muscular Dystrophy (DMD) and Myotonic Dystrophy Type 1 (DM1) by expanding its collaboration with CRISPR Therapeutics and acquiring Exonics Therapeutics.
The Zacks Analyst Blog Highlights: Vertex Pharmaceuticals, Gilead Sciences, Repligen, Illumina and Bio-Techne
here are a few stocks that have outperformed their peers and are expected to have continued growth throughout the next couple of years. All the stocks in this list are a Zacks Rank 2 (Buy) or better.
Vertex Pharmaceuticals Incorporated (VRTX) today announced that data from six scientific abstracts from the company’s portfolio of cystic fibrosis (CF) medicines will be presented at the 42nd European Cystic Fibrosis Conference, taking place June 5-8, 2019 in Liverpool, UK. These abstracts include data being presented from the ongoing Phase 3 ARRIVAL study of the pharmacokinetics (PK) and safety of KALYDECO® (ivacaftor) in a cohort of patients 6 to
Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is...
Vertex (VRTX) choses VX-445 triple combination regimen for global regulatory submissions to seek approval for the regimen as a treatment for cystic fibrosis based on 24-week phase III study data.
-Mean absolute improvement in ppFEV1 of 14.3 percentage points from baseline through week 24 of treatment compared to placebo in patients with one F508del m